SAS Output

26-APR-2018 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1606 362 203 113 38 1 07/08/2014 433 218
            1606 362 203 113 38 1      
 
    2 Y 17 S1400G   56 44 24 13 6 3      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        21 S1400F   47 47 43 24 6 0      
        25 S1400K   22 22 22 22 7 2      
        3 S1400B   53 0 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 0 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   700 183 65 29 15 1      
            1234 296 154 88 34 6      
 
    3 P 10 S1400I   13 7 5 3 0 0      
        18 S1400G   10 7 2 2 0 0      
        22 S1400F   12 12 12 8 2 0      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            36 26 19 13 2 0      
 
    4 P 23 S1400F   2 2 2 1 0 0 07/08/2014    
            2 2 2 1 0 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 1 0 0 0 0 07/31/2014    
            4 1 0 0 0 0      
 
  S1400F-Non-Match: MEDI4736 + Tremelimumab 1 Y 1 MEDI4736 + Tremelimumab 132 17 17 17 10 4 2 11/30/2017   218
            17 17 17 10 4 2      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 45 39 15 10 5 0 03/03/2017 431 218
            45 39 15 10 5 0      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 N 1 Nivolumab + Ipilimumab 350 138 43 21 8 3 1 12/29/2015 430 217
        2 Nivolumab   137 42 16 10 2 0      
            275 85 37 18 5 1      
 
  S1400K-c-Met: ABBV-399 (Process II) 1 Y 1 ABBV-399 (Process II) 44 8 8 8 8 6 2 03/16/2018   202
            8 8 8 8 6 2      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 N 1 AFATINIB + CETUXIMAB 605 89 38 16 10 2 0 05/07/2015 221 96
        2 AFATINIB   85 36 13 4 1 0      
            174 74 29 14 3 0      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 N 5 RT+Pac+Carbo+blinded drug 132 18 9 0 0 0 0 01/24/2013 94 39
        6 RT+Pac+Carbo+blinded drug   14 5 0 0 0 0      
            32 14 0 0 0 0      
 
    2 Y 8 Pac + Carbo + blinded drug 132 23 20 3 0 0 0 01/24/2013    
            23 20 3 0 0 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   38 18 10 5 1 0 04/01/2015   251
            38 18 10 5 1 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   493 214 107 66 23 4 12/16/2014 455 256
            493 214 107 66 23 4      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   55 5 3 0 0 0 05/14/2008 228 118
            55 5 3 0 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   7 4 1 0 0 0 02/29/2016 464 254
            7 4 1 0 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 3 0 0 0 0 10/20/2016 319 138
            4 3 0 0 0 0      
 
    2 E Total Registrations   4 3 0 0 0 0 10/20/2016    
            4 3 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   499 215 106 66 20 4 12/16/2014 455 256
            499 215 106 66 20 4      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   43 33 19 7 2 0 08/03/2016 410 237
            43 33 19 7 2 0      
 

26-APR-2018 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 Neoadjuvant Therapy 03-Nov-17
  2 Surgery 03-Nov-17
  3 Maintenance 03-Nov-17

26-APR-2018 6:10

LUNG Recently Closed Studies Accrual Report

The REPORT Procedure

Detailed and/or summarized report

Table 1

OPEN Study Date
Closed
Reg. Arm Total
Regs
Regs
Last
30 Days
Regs
Last
7 Days
N S1400I-Non-Match: Nivo + Ipi vs Nivo 23-Apr-18 1 1 Nivolumab + Ipilimumab 138 3 1
        2 Nivolumab 137 2 0
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 23-Apr-18 1 1 AFATINIB + CETUXIMAB 89 2 0
        2 AFATINIB 85 1 0